Wu Fei-Fei, He Xiao-Feng, Shen Hu-Wei, Qin Gui-Jun
Department of Endocrinology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Department of Research, Peace Hospital of Changzhi Medical College, Changzhi, China.
PLoS One. 2014 Sep 11;9(9):e87764. doi: 10.1371/journal.pone.0087764. eCollection 2014.
The previous published data on the association between the X-ray repair cross-conplementation group 1 (XRCC1) polymorphisms and thyroid cancer risk remained controversial. Hence, we performed a meta-analysis on all available studies that provided 1729 cases and 3774 controls (from 11 studies) for XRCC1 Arg399Gln, 1040 cases and 2487 controls for Arg194Trp (from 7 studies), and 1432 cases and 3356 controls for Arg280His (from 8 studies).
METHODOLOGY/PRINCIPAL FINDINGS: PubMed, CNKI, and EMBASE database were searched to identify relevant studies. Overall, no significant association was found between XRCC1 Arg399Gln (recessive model: OR = 0.95, 95% CI = 0.77-1.15; dominant model: OR = 0.89, 95% CI = 0.75-1.05; homozygote model: OR = 0.92, 95% CI = 0.69-1.23; Heterozygote model: OR = 0.91, 95% CI = 0.80-1.03; additive model: OR = 0.93, 95% CI = 0.81-1.07), Arg194Trp (recessive model: OR = 1.41, 95% CI = 0.62-3.23; dominant model: OR = 1.01, 95% CI = 0.77-1.34; homozygote model: OR = 1.42, 95% CI = 0.55-3.67; Heterozygote model: OR = 1.03, 95% CI = 0.85-1.26; additive model: OR = 1.08, 95% CI = 0.81-1.42), and Arg280His (recessive model: OR = 1.08, 95% CI = 0.56-2.10; dominant model: OR = 1.01, 95% CI = 0.84-1.22; homozygote model: OR = 1.00, 95% CI = 0.51-1.96; Heterozygote model: OR = 1.04, 95% CI =0.75-1.42; additive model: OR = 1.03, 95% CI = 0.86-1.23) and thyroid cancer risk when all the eligible studies were pooled into the meta-analysis. In the further stratified and sensitivity analyses, significant association was still not found in these three genetic polymorphisms.
CONCLUSIONS/SIGNIFICANCE: In summary, this meta-analysis indicates that XRCC1 Arg399Gln, Arg280His, and Arg194Trp are not associated with thyroid cancer.
先前发表的关于X射线修复交叉互补基因1（XRCC1）多态性与甲状腺癌风险之间关联的数据仍存在争议。因此，我们对所有可用研究进行了荟萃分析，这些研究提供了1729例病例和3774例对照（来自11项研究）用于XRCC1 Arg399Gln分析，1040例病例和2487例对照用于Arg194Trp分析（来自7项研究），以及1432例病例和3356例对照用于Arg280His分析（来自8项研究）。
方法/主要发现：检索PubMed、CNKI和EMBASE数据库以识别相关研究。总体而言，当将所有符合条件的研究纳入荟萃分析时，未发现XRCC1 Arg399Gln（隐性模型：OR = 0.95，95%CI = 0.77 - 1.15；显性模型：OR = 0.89，95%CI = 0.75 - 1.05；纯合子模型：OR = 0.92，95%CI = 0.69 - 1.23；杂合子模型：OR = 0.91，95%CI = 0.80 - 1.03；加性模型：OR = 0.93，95%CI = 0.81 - 1.07）、Arg194Trp（隐性模型：OR = 1.41，95%CI = 0.62 - 3.23；显性模型：OR = 1.01，95%CI = 0.77 - 1.34；纯合子模型：OR = 1.42，95%CI = 0.55 - 3.67；杂合子模型：OR = 1.03，95%CI = 0.85 - 1.26；加性模型：OR = 1.08，95%CI = 0.81 - 1.42）和Arg280His（隐性模型：OR = 1.08，95%CI = 0.56 - 2.10；显性模型：OR = 1.01, 95%CI = 0.84 - 1.22；纯合子模型：OR = 1.00，95%CI = 0.51 - 1.96；杂合子模型：OR = 1.04，95%CI = 0.75 - 1.42；加性模型：OR = 1.03，95%CI = 0.86 - 1.23）与甲状腺癌风险之间存在显著关联。在进一步的分层分析和敏感性分析中，这三种基因多态性仍未发现显著关联。
结论/意义：总之，这项荟萃分析表明XRCC1 Arg399Gln、Arg280His和Arg194Trp与甲状腺癌无关。
